AMN / NEWS DESK
US President Donald Trump has announced sweeping agreements with major pharmaceutical companies to lower prescription drug costs, calling it the biggest cut in drug prices in the US history.
Speaking at the White House, President Trump said one of the leading firms, Regeneron, had agreed to offer medicines at most-favoured-nation prices, adding that the numbers will come down at levels that nobody’s ever seen before.
With this announcement, 17 of the world’s largest pharmaceutical companies, representing 80% of the branded drug market, have now agreed to sell their drugs to American patients at the lowest prices anywhere in the world, he said. The President argued that Americans had long paid disproportionately high prices. The White House said the agreements now cover about 86% of the branded pharmaceutical market, with further negotiations underway
The policy shift comes amid long-standing criticism that Americans pay far more for prescription drugs than patients in countries like Canada, Germany, and the United Kingdom, where government-backed pricing systems keep costs in check. By linking US drug prices to global benchmarks, the administration hopes to close this gap and curb rising healthcare expenses.
However, industry experts caution that implementation could face legal and logistical hurdles, particularly around international price comparisons and supply chain adjustments. Pharmaceutical companies have also expressed concerns that steep price cuts may impact innovation and research investments.
Despite these challenges, the move is being seen as a significant shift in US healthcare policy, with potential ripple effects across global pharmaceutical markets. If fully executed, the initiative could redefine pricing strategies not just in America, but worldwide.